Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Each year, Phesi releases an analysis of the world’s most studied diseases. The survey includes data from the 67,569 ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI compares ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

In this part of his Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, explores the contributing ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI identifies ...

Biljana Naumovic discusses how a new study attempted to bring in patients from underserved communities.

In this Pharmaceutical Executive video interview, Ian Baer, Founder & CEO of Sooth, identifies how uncertainty of where to find information, coupled with distrust, can damage the relationship between ...

A Harvard Business School Healthcare Alumni Association Q&A with Spencer Stuart’s Claudius A. Hildebrand.

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...